Stay updated on Nivolumab & Cabozantinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Cabozantinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.
Latest updates to the Nivolumab & Cabozantinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 135 locations, and the website has been updated to version 2.10.0, replacing the previous version 2.9.7.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check24 days agoChange DetectedThe change in the web page value represents an update to the Erratum information for the study 'Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER)' published in Lancet Oncology. The updated Erratum information includes a new DOI reference: doi: 10.1016/S1470-2045(22)00346-1.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check29 days agoChange DetectedThe value on the web page has recently changed to FDA Safety Alerts and Recalls, indicating a shift in the content focus towards safety alerts and recalls issued by the FDA.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.1%
Stay in the know with updates to Nivolumab & Cabozantinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Cabozantinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.